Prostatic radioimmunoscintigraphy: preliminary results using technetium‐labelled monoclonal antibody, CYT‐351

Feneley, Mark; Chengazi, Vaseem; Kirby, Roger; Nimmon, C.C.; Granowska, M.; Mather, Stephen J.; Ellison, David H.; Granowski, A.; Britton, K. E.

doi:10.1046/j.1464-410x.1996.09099.x

Cited by 16 publications

(10 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PSMA radionuclide scan is one such investigation which needs careful consideration. It is clear that the results with 99m Tc‐MUJ591 are, despite its theoretical advantages in reacting with an external domain of PSMA, less satisfactory than those using 99m Tc‐CYT351 against the internal domain [21,22]. This might be a result of greater fragility of antibody labelling using the photo‐reduction than with the standard reduction method used for monoclonal labelling with 99m Tc [25].…”

Section: Discussionmentioning

confidence: 99%

Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate‐specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging

Nargund¹,

Hashmi

Kumar³

et al. 2005

BJU International

View full text Add to dashboard Cite

radiolabelled with 99m Tc using a photoreduction technique. RESULTSThe findings of prostate imaging and histology were identical in seven patients. Scans showed understaging and overstaging in six and three patients, respectively. CONCLUSIONSPSMA scintigraphy using 99m Tc-labelled MUJ591 identifies the presence of prostate cancer, but is not sensitive in delineating micro-invasion of the capsule, seminal vesicles or bladder neck. As in other studies it seems to be useful in detecting prostate bed recurrence and distant micrometastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate‐specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging

Nargund¹,

Hashmi

Kumar³

et al. 2005

BJU International

View full text Add to dashboard Cite

show abstract

“…4 Prostatic immunoscintigraphy using technetium-99m as the radiolabel also offers excellent imaging characteristics, as well as signi®-cant cost and radiation advantages over indium-111. 10 Primary malignancy within the prostate is associated with substantially greater signal strength and uptake of antibody than benign prostatic tissue. Although this may be clearly evident in some scans, their interpretation is somewhat observer dependent and quantitative analysis (the`image surgery' technique 13 ) that would permit objective assessment of test sensitivity and speci®city is not yet available.…”

Section: Discussionmentioning

confidence: 99%

Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer

Feneley¹,

Jan²,

Granowska³

et al. 2000

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Radioimmunoscintigraphy using a radio-labelled antibody to prostate-speci®c membrane antigen (PSMA) has growing applications as a means of tissuespeci®c imaging based on functional characteristics and complements traditional staging investigations. Clinical applications in men with carcinoma of the prostate are being re®ned, and this study reports outcomes with this technique in our practice. Prostatic immunoscintigraphy scans were performed with In-111 CYT 356 in 49 men with carcinoma of the prostate, obtaining sequential images in two and three dimensions at 10 min, 24 and 48 h. Of the 49 men, 36 had clinically localized cancer, 10 had recurrent disease after radical radiotherapy or radical prostatectomy and three had rising PSA after primary endocrine treatment. Scan ®ndings are discussed in the context of clinical management. Of the 36 men with clinically localized cancer, seven had increased uptake in regional and distant lymph nodes. Of these seven, three were treated with hormone manipulation, two by radical prostatectomy and two by radical radiotherapy. Among 10 patients who had recurrence after radical treatment of the primary tumour, scans showed local recurrence alone in four, and six had regional or distant metastases. Three patients treated with primary hormone manipulation had scans for rising PSA, and of these one had a positive regional node and two had distant soft tissue and bone metastases. In conclusion, prostatic radio-immunoscintigraphy scans highlight tissues involved by prostate cancer, including the prostate, lymph nodes, soft tissues and bone metastases as well as pelvic recurrence. Results may contribute to the clinical management of individual patients, although histological con®rmation may be appropriate when considering alternative treatment. Prostate Cancer and Prostatic Diseases (2000) 3, 47±52.

show abstract

“…Therefore, a new radioimmunoconjugate, 99m Tc‐7E11‐C5.3, also called as CYT‐351, was prepared and demonstrated to show considerable advantages over ProstaScint scan. The merits are due to attractive features of 99m Tc radioisotope that are short half‐life ( t 1/2 = 6.02 hours), low radiation dose, affordable cost, minimal bone marrow uptake, and short scan session thereby avoiding the usage of laxatives . CYT‐351 is derived from bis (thiosemicarbazone) technetium chelating ligand, CYT‐395, having a free hydrazide side chain available for conjugation with mAb (7E11‐C5.3) sugar moiety.…”

Section: Prostate Cancer Biomarkermentioning

confidence: 99%

Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer

et al. 2019

View full text Add to dashboard Cite

Background Prostate‐specific membrane antigen (PSMA), overexpressed on prostate cancer (PCa), is a well‐characterized cell surface protein to selectively diagnose PCa. PSMA's unique characteristics and its 1000‐fold higher expression in PCa compared with other tissues renders it as a suitable biomarker for detection of PCa in its early stage. In this report, we critically analyze and recommend the requirements needed for the development of variety of PSMA‐targeted molecular imaging agents based on antibodies, small molecule ligands, peptides, and aptamers. The targeting moieties are either conjugated to radionuclear isotopes or near‐infrared agents for efficient diagnosis of PCa. Recent findings From the analysis, it was found that several small molecule–derived PCa imaging agents are approved for clinical trials in Europe and the United States, and few are already in the clinical use for diagnosis of PCa. Even though 111In‐labeled capromab pendetide was approved by the Food and Drug Administration (FDA) and other engineered antibodies are available for detection of PCa, but high production cost, low shelf life (less than 1 month at 4°C), possibility of human immuno reactions, and low blood clearance rate necessitated a need for developing new imaging agents, which are serum stable, cost‐effective, and possesses longer shelf life (6 months), have fast clearance rate from nontargeted tissues during the diagnosis process. It is found that small molecule ligand‐derived imaging agents possesses most of the desired properties expected for an ideal diagnostic agent when compared with other targeting moieties. Conclusion This report discusses in detail the homing moieties used in the development of targeted diagnostic tools for detection of PCa. The merits and demerits of monoclonal antibodies, small molecule ligands, peptides, and aptamers for imaging of PCa and intraoperative guided surgery are extensively analyzed. Among all, urea‐based ligands were found to be most successful in preclinical and clinical trials and show a major promise for future commercialization.

show abstract

Prostatic radioimmunoscintigraphy: preliminary results using technetium‐labelled monoclonal antibody, CYT‐351

Cited by 16 publications

References 1 publication

Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate‐specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging

Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate‐specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging

Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer

Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer

Contact Info

Product

Resources

About